2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Monday, November 11, 2019

9:00AM-11:00AM: Abstract Number: 1610

Prediction of Organ Damage Accrual in Systemic Lupus Erythematosus Using a Frailty Index

SLE – Clinical Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: 1300

Predictor of Placebo Response in Hand Osteoarthritis: A Post Hoc Analysis of Two Randomized Controlled Trials

Osteoarthritis – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 1715

Predictors of Gastrointestinal and Renal Involvement in Adult IgA Vasculitis

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Behçet’s Disease & Other Vasculitides

9:00AM-11:00AM: Abstract Number: 1137

Predictors of Health-Related Quality of Life in Patients with Musculoskeletal Diseases: A Longitudinal Analysis from an Electronic Health Record Database

Health Services Research Poster II – ACR/ARP

9:00AM-11:00AM: Abstract Number: 1430

Predictors of Response to Etanercept-Methotrexate Treatment: Post-hoc Analysis of a Randomized, Open-label Study in Latin American Patients with Rheumatoid Arthritis

RA – Treatments Poster II: Established Treatments

9:00AM-11:00AM: Abstract Number: 1544

Predictors of Response, Adverse Events and Treatment Retention in Ankylosing Spondylitis Patients Treated with Golimumab in a Prospective, Observational Registry

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1418

Predictors of Response, Adverse Events and Treatment Retention in RA Patients Treated with Either Subcutaneous- or Intravenous- Golimumab in a Prospective, Observational Registry

RA – Treatments Poster II: Established Treatments

9:00AM-11:00AM: Abstract Number: 1579

Presence of Antiphospholipid Antibodies in Patients with SLE and Venous Thromboembolic Events of African American and Caucasian Race

SLE – Clinical Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: 1576

Prevalence and Outcome of Thrombocytopenia in Systemic Lupus Erythematosus – Single Centre Cohort Analysis

SLE – Clinical Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: 1120

Prevalence of Burnout in Rheumatology Professionals

Health Services Research Poster II – ACR/ARP

9:00AM-11:00AM: Abstract Number: 1589

Prevalence of Cognitive Impairment in an Inception Lupus Cohort as Assessed by a Comprehensive Neuropsychological Battery

SLE – Clinical Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: 1103

Prevalence of Diagnosed Systemic Lupus Erythematosus (SLE), Patient Healthcare Utilization and Characteristics by Major Health Insurance Types in the US

Epidemiology & Public Health Poster II: Spondyloarthritis & Connective Tissue Disease

9:00AM-11:00AM: Abstract Number: 1601

Prevalence of Peripheral Neuropathy and Its Electrophysiological Types in Patients with Systemic Lupus Erythematosus

SLE – Clinical Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: 1174

Prevalence of Subclinical Sacroiliitis in Young Patients with Inflammatory Bowel Disease Revealed by Entero-MRI

Imaging Of Rheumatic Diseases Poster II

9:00AM-11:00AM: Abstract Number: 1311

Prevalence of Symptomatic Axial Osteoarthritis and Poliarticular Phenotypes in Spain: EPISER 2016 Study

Osteoarthritis – Clinical Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].